Celgene’s Receptos Deal Almost Came Billions Cheaper in 2013

When Celgene Corp. agreed to buy Receptos Inc. for $7.2 billion this month, both companies soared on the news. Little did investors know that Celgene had a Receptos deal in its grasp in 2013, when the drugmaker was trading for an eighth of the final price.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.